Rocilinostat (ACY-1215) |cas 1316214-52-4| DC Chem|Supplier|Price|Buy  

Rocilinostat (ACY-1215) |cas 1316214-52-4| DC Chem|Supplier|Price|Buy

DC Chemicals Supply: Rocilinostat (ACY-1215) |cas 1316214-52-4,Purity: >98% ,Cat No. DC7048, In stock.

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642517；

Rocilinostat (ACY-1215) |cas 1316214-52-4 ,Synonym: Rocilinostat; ACY1215; ACY 1215  ,Chemical name: 5-Pyrimidinecarboxamide,2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]- ,Molecular Formula: C24H27N5O3 ,MW:433.5

Rocilinostat (ACY-1215) , cas 1316214-52-4,Purity: >98%, Best Price and quality from DC Chemicals. Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM; >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2.

ACY-1215 is a hydroxamic acid derivative. ACY-1215 is 12-, 10-, and 11-fold less active against HDAC1, HDAC2, and HDAC3 (class I HDACs), respectively. ACY-1215 has minimal activity (IC50 > 1μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2, and has slight activity against HDAC8 (IC50 = 0.1μM). The IC50 values for ACY-1215 for T-cell toxicity is 2.5μM. ACY-1215 overcomes tumor cell growth and survival conferred by BMSCs and cytokines in the BM milieu. ACY-1215 in combination with bortezomib induces synergistic anti-MM activity. ACY-1215 induces potent acetylation of α-tubulin at very low doses and triggers acetylation of lysine on histone H3 and histone H4 only at higher doses, confirming its specific inhibitory effect on HDAC6 activity. [1] ACY-1215 in combination with bortezomib triggered more significant anti-MM activity than either agent alone in suppressing tumor growth and prolonging survival in both plasmacytoma model and disseminated MM model without significant adverse effects. ACY-1215 is readily absorbed by tumor tissue. Moreover, the drug does not accumulate in tumor tissue, as evidenced by the parallel decline of acetylated α-tubulin in blood cells and tumor tissue by 24 hours after dose. [1]